A lung cancer drug called osimertinib kept 55% of patients alive without their cancer worsening after seven years — compared with just 3% of patients on the previous standard treatment, according to long-term data from the landmark FLAURA clinical trial published in late May 2026 and announced via Business Wire. The results were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting.
The trial tracked patients with advanced non-small cell lung cancer (NSCLC) who carried a specific genetic change called an EGFR mutation — a subset that accounts for roughly 10–15% of all NSCLC cases in the United States, and a much higher share in East Asian populations. Osimertinib, sold under the brand name Tagrisso and developed by AstraZeneca, targets that mutation directly rather than hitting cancer cells broadly the way traditional chemotherapy does.
What the 7-Year FLAURA Data Actually Shows
The 55% progression-free survival figure is the headline number, but the more telling comparison is what sits next to it: only 3% of patients on earlier-generation EGFR inhibitors — erlotinib or gefitinib — were still progression-free at the same seven-year mark. That gap, 55 percentage points, is unusually wide for any oncology head-to-head trial and reflects how decisively osimertinib outpaced its predecessors over time.
Progression-free survival measures the length of time during and after treatment in which a patient’s cancer does not grow or spread. It is a meaningful clinical benchmark because cancer growth typically brings worsening symptoms, additional treatment rounds, and declining quality of life.
The FLAURA trial is a randomized, double-blind, Phase III study — the gold standard in clinical research — which gives the seven-year follow-up data particular weight. Most lung cancer drug trials report outcomes at two or three years; seven-year data in advanced lung cancer is rare enough that oncologists have described this follow-up period as “unprecedented” for this disease stage.
Why Osimertinib Pulls So Far Ahead Over Time
Earlier EGFR-targeted drugs worked well initially but eventually lost effectiveness as tumors developed a secondary resistance mutation called T790M. Osimertinib was engineered to block both the original EGFR mutation and T790M simultaneously, which is why the drug’s benefit compounds over years rather than plateauing or reversing.
That design difference helps explain why the gap between osimertinib and older targeted therapies widens so dramatically at the seven-year mark — patients on earlier drugs who progressed often needed further treatment lines, each of which carries its own risks and diminishing returns.
The drug already carries approval from the U.S. Food and Drug Administration for first-line treatment of EGFR-mutated metastatic NSCLC, as well as for earlier-stage disease following surgery. The new long-term data bolsters the case for its continued front-line use and may influence how oncologists counsel patients about treatment sequencing.
Who This Affects in the U.S.
Lung cancer remains the leading cause of cancer death in the United States. The American Cancer Society estimates that roughly 234,000 new lung cancer cases are diagnosed in the U.S. each year. Of those, NSCLC accounts for about 80–85% of cases, meaning the EGFR-mutated population that osimertinib targets numbers in the tens of thousands annually.
For those patients, the FLAURA seven-year data shifts what “long-term remission” can realistically look like. Before targeted therapies, median survival for advanced NSCLC was measured in months. The fact that more than half the osimertinib group in FLAURA remained progression-free after seven years suggests a functional long-term remission — not a cure, but a sustained suppression that can run alongside a near-normal life.
Access remains a real variable. Tagrisso carries a high list price, and while most major insurers cover it for FDA-approved indications, out-of-pocket costs vary significantly by plan. AstraZeneca offers a patient assistance program, though eligibility thresholds can be restrictive. For patients navigating coverage questions, the cancer treatment landscape is shifting rapidly — much as millions of Americans facing insurance disruptions are discovering across multiple disease areas this year.
What Comes After the ASCO Presentation
Full peer-reviewed publication of the seven-year FLAURA data in a major oncology journal is expected to follow the ASCO presentation, which is standard practice for trial results unveiled at the conference. Once published, the data will enter the evidence base that oncology guidelines committees — including those at the National Comprehensive Cancer Network — use to update official treatment recommendations.
Researchers are also watching several ongoing trials that combine osimertinib with other agents, including chemotherapy and antibody-drug conjugates, to see whether the seven-year bar can be pushed further. AstraZeneca has additional EGFR-targeted compounds in its pipeline targeting patients whose cancers eventually develop resistance even to osimertinib — the next unsolved problem in this corner of lung oncology.
For patients diagnosed today with EGFR-mutated advanced NSCLC, their oncologist is almost certainly already starting a conversation about this drug. The seven-year data gives that conversation a very different starting point than it had even three years ago.
